Research
Hormonal
Tirzepatide should be used in combination with CPAP for patients with severe OSA, as the drug takes 6-12 months to significantly reduce AHI, leaving patients at risk during the interim.
If you have severe OSA, do not stop CPAP when starting tirzepatide. The drug takes 6-12 months to significantly reduce your apnea. Use CPAP nightly during this period to protect your heart and safety. After a year, if your AHI has dropped significantly, you and your doctor can discuss tapering off CPAP.
GoodQualifiesHIGH confidence
Tirzepatide should not be used alone in patients with severe OSA since it will take 6 months to a year for clinical improvement. Patients with severe OSA could have a myocardial infarction, stroke, develop hypertension or have a fall-asleep motor vehicle accident during the 6 months to a year that it takes tirzepatide to improve the AHI.
Why this rating
Based on expert opinion and the known time course of weight loss from the SURMOUNT-OSA trial.
Source
What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)?
Allan I Pack et al. · SLEEP · 2025
DOI 10.1093/sleep/zsaf045
narrative_reviewCited 9×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide significantly reduces apnea-hypopnea index (AHI) and resolves obstructive sleep apnea (OSA) in obese patients, with approximately 50% achieving resolution after 52 weeks of treatment.Strong
- Tirzepatide may allow some patients with moderate OSA (AHI 15-30) who are asymptomatic (except for snoring) to discontinue CPAP, as the benefit of CPAP in this subgroup is unclear.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →